Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.

• Crossref
• PubMed
Bray F, Ferlay J, Soerjomataram I, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.10.3322/caac.2149230207593)| false
• Search Google Scholar
• Export Citation

Jordan EJ, Kim HR, Arcila ME, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov 2017;7:596–609.

• Crossref
• PubMed
Jordan EJ, Kim HR, Arcila ME, Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov 2017;7:596–609.2833655210.1158/2159-8290.CD-16-1337)| false
• Search Google Scholar
• Export Citation

Aran V, Omerovic J. Current approaches in NSCLC targeting K-RAS and EGFR. Int J Mol Sci 2019;20:5701.

• Crossref
• PubMed
Aran V, Omerovic J. Current approaches in NSCLC targeting K-RAS and EGFR. Int J Mol Sci 2019;20:5701.10.3390/ijms20225701)| false
• Search Google Scholar
• Export Citation

Fang S, Wang Z. EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. Drug Des Devel Ther 2014;8:1595–1611.

• PubMed
Fang S, Wang Z. EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. Drug Des Devel Ther 2014;8:1595–1611.25302015)| false
• Search Google Scholar
• Export Citation

Voldborg BR, Damstrup L, Spang-Thomsen M, et al. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 1997;8:1197–1206.

• Crossref
• PubMed
Voldborg BR, Damstrup L, Spang-Thomsen M, Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 1997;8:1197–1206.949638410.1023/A:1008209720526)| false
• Search Google Scholar
• Export Citation

Wang J, Wang B, Chu H, et al. Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. OncoTargets Ther 2016;9:3711–3726.

• Crossref
• PubMed
Wang J, Wang B, Chu H, Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. OncoTargets Ther 2016;9:3711–3726.10.2147/OTT.S106399)| false
• Search Google Scholar
• Export Citation

Zhang YL, Yuan JQ, Wang KF, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 2016;7:78985–78993.

• Crossref
• PubMed
Zhang YL, Yuan JQ, Wang KF, The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 2016;7:78985–78993.10.18632/oncotarget.1258727738317)| false
• Search Google Scholar
• Export Citation

Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis 2016;10:113–129.

• Crossref
• PubMed
Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis 2016;10:113–129.10.1177/1753465815617871)| false
• Search Google Scholar
• Export Citation

Castellanos E, Feld E, Horn L. Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer. J Thorac Oncol 2017;12:612–623.

• Crossref
• PubMed
Castellanos E, Feld E, Horn L. Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer. J Thorac Oncol 2017;12:612–623.2801778910.1016/j.jtho.2016.12.014)| false
• Search Google Scholar
• Export Citation

Yang JC-H, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 2015;16:830–838.

• Crossref
• PubMed
Yang JC-H, Sequist LV, Geater SL, Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 2015;16:830–838.2605123610.1016/S1470-2045(15)00026-1)| false
• Search Google Scholar
• Export Citation

Robichaux JP, Elamin YY, Tan Z, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 2018;24:638–646.

• Crossref
• PubMed
Robichaux JP, Elamin YY, Tan Z, Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 2018;24:638–646.2968642410.1038/s41591-018-0007-9)| false
• Search Google Scholar
• Export Citation

Wu JY, Yu CJ, Chang YC, et al. Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011;17:3812–3821.

• Crossref
• PubMed
Wu JY, Yu CJ, Chang YC, Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011;17:3812–3821.2153181010.1158/1078-0432.CCR-10-3408)| false
• Search Google Scholar
• Export Citation

Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 2019;30: 1321–1328.

• Crossref
• PubMed
Mazieres J, Drilon A, Lusque A, Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 2019;30: 1321–1328.10.1093/annonc/mdz16731125062)| false
• Search Google Scholar
• Export Citation

Negrao MV, Skoulidis F, Montesion M, et al. BRAF mutations are associated with increased benefit from PD1/PDL1 blockade compared with other oncogenic drivers in non-small cell lung cancer. J Thorac Oncol 2019;14(Suppl 10):S257–258.

• Crossref
• PubMed
Negrao MV, Skoulidis F, Montesion M, BRAF mutations are associated with increased benefit from PD1/PDL1 blockade compared with other oncogenic drivers in non-small cell lung cancer. J Thorac Oncol 2019;14(Suppl 10):S257–258.10.1016/j.jtho.2019.08.514)| false
• Search Google Scholar
• Export Citation

Ettinger DS, Wood SDE, Aisner DL, et al. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 5.2021. Accessed June 15, 2021. To view the most recent version, visit NCCN.org

• PubMed
Ettinger DS, Wood SDE, Aisner DL, NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 5.2021. Accessed June 15, 2021. To view the most recent version, visit NCCN.org)| false
• Search Google Scholar
• Export Citation

American Society of Clinical Oncology. Molecular testing guidelines for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors. Accessed September 15, 2021. Available at: https://www.asco.org/sites/new-www.asco.org/files/content-files/practice-and-guidelines/documents/2018-lung-markers-endorsement-table.pdf

• PubMed
American Society of Clinical Oncology. Molecular testing guidelines for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors. Accessed September 15, 2021. Available at: https://www.asco.org/sites/new-www.asco.org/files/content-files/practice-and-guidelines/documents/2018-lung-markers-endorsement-table.pdf)| false
• Search Google Scholar
• Export Citation

Rolfo C, Mack PC, Scagliotti GV, et al. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC. J Thorac Oncol 2018;13:1248–1268.

• Crossref
• PubMed
Rolfo C, Mack PC, Scagliotti GV, Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC. J Thorac Oncol 2018;13:1248–1268.2988547910.1016/j.jtho.2018.05.030)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. FDA broadens afatinib indication to previously untreated metastatic NSCLC with other non-resistant EGFR mutations. Accessed June 10, 2021. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-broadens-afatinib-indication-previously-untreated-metastatic-nsclc-other-non-resistant-egfr

• PubMed
U.S. Food & Drug Administration. FDA broadens afatinib indication to previously untreated metastatic NSCLC with other non-resistant EGFR mutations. Accessed June 10, 2021. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-broadens-afatinib-indication-previously-untreated-metastatic-nsclc-other-non-resistant-egfr)| false
• Search Google Scholar
• Export Citation

Guo G, Li G, Liu Y, et al. Next-generation sequencing reveals high uncommon EGFR mutations and tumour mutation burden in a subgroup of lung cancer patients. Front Oncol 2021;11:621422.

• Crossref
• PubMed
Guo G, Li G, Liu Y, Next-generation sequencing reveals high uncommon EGFR mutations and tumour mutation burden in a subgroup of lung cancer patients. Front Oncol 2021;11:621422.10.3389/fonc.2021.621422)| false
• Search Google Scholar
• Export Citation

Yang JCH, Schuler M, Popat S, et al. Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases. J Thorac Oncol 2020;15:803–815.

• Crossref
• PubMed
Yang JCH, Schuler M, Popat S, Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases. J Thorac Oncol 2020;15:803–815.10.1016/j.jtho.2019.12.12631931137)| false
• Search Google Scholar
• Export Citation

Hanna NH, Robinson AG, Temin S, et al. Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) Joint Guideline Update. J Clin Oncol 2021;39:1040–1091.

• Crossref
• PubMed
Hanna NH, Robinson AG, Temin S, Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) Joint Guideline Update. J Clin Oncol 2021;39:1040–1091.3359184410.1200/JCO.20.03570)| false
• Search Google Scholar
• Export Citation

Thress KS, Jacobs V, Angell HK, et al. Modulation of biomarker expression by osimertinib: results of the paired tumor biopsy cohorts of the AURA phase 1 trial. J Thorac Oncol 2017;12:1588–1594.

• Crossref
• PubMed
Thress KS, Jacobs V, Angell HK, Modulation of biomarker expression by osimertinib: results of the paired tumor biopsy cohorts of the AURA phase 1 trial. J Thorac Oncol 2017;12:1588–1594.10.1016/j.jtho.2017.07.011)| false
• Search Google Scholar
• Export Citation

Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017;376:629–640.

• Crossref
• PubMed
Mok TS, Wu YL, Ahn MJ, Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017;376:629–640.10.1056/NEJMoa1612674)| false
• Search Google Scholar
• Export Citation

Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378:113–125.

• Crossref
• PubMed
Soria JC, Ohe Y, Vansteenkiste J, Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378:113–125.2915135910.1056/NEJMoa1713137)| false
• Search Google Scholar
• Export Citation

Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 2020;382:41–50.

• Crossref
• PubMed
Ramalingam SS, Vansteenkiste J, Planchard D, Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 2020;382:41–50.10.1056/NEJMoa191366231751012)| false
• Search Google Scholar
• Export Citation

Cho JH, Lim SH, An HJ, et al. Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol 2020;38:488–495.

• Crossref
• PubMed
Cho JH, Lim SH, An HJ, Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol 2020;38:488–495.10.1200/JCO.19.0093131825714)| false
• Search Google Scholar
• Export Citation

Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci 2016;107:1179–1186.

• Crossref
• PubMed
Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci 2016;107:1179–1186.10.1111/cas.1299627323238)| false
• Search Google Scholar
• Export Citation

Girard N, Bazhenova L, Minchom A, et al. Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Presented at the 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28–31, 2021; Singapore.

• PubMed
Girard N, Bazhenova L, Minchom A, Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Presented at the 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28–31, 2021; Singapore.34818606)| false
• Search Google Scholar
• Export Citation

Naldoo J, Sima CS, Rodriguez K, et al. Epidermal growth factor receptor exon 20 insertions in advanced lung cell adenocarcinomas: clinical outcomes and response to erlotinib. Cancer 2015;121:3212–3220.

• Crossref
• PubMed
Naldoo J, Sima CS, Rodriguez K, Epidermal growth factor receptor exon 20 insertions in advanced lung cell adenocarcinomas: clinical outcomes and response to erlotinib. Cancer 2015;121:3212–3220.10.1002/cncr.29493)| false
• Search Google Scholar
• Export Citation

Piotrowska Z, Wang Y, Sequist LV, et al. ECOG-ACRIN 5162: a phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions [abstract]. J Clin Oncol 2020;38(Suppl):Abstract 9513.

• Crossref
• PubMed
Piotrowska Z, Wang Y, Sequist LV, ECOG-ACRIN 5162: a phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions [abstract]. J Clin Oncol 2020;38(Suppl):Abstract 9513.10.1200/JCO.2020.38.15_suppl.9513)| false
• Search Google Scholar
• Export Citation

Negrao MV, Reuben A, Robichaux JP, et al. Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer [abstract]. J Clin Oncol 2018;36(Suppl):Abstract 9052.

• Crossref
• PubMed
Negrao MV, Reuben A, Robichaux JP, Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer [abstract]. J Clin Oncol 2018;36(Suppl):Abstract 9052.10.1200/JCO.2018.36.15_suppl.9052)| false
• Search Google Scholar
• Export Citation

U.S. Food & Drug Administration. FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer. Accessed July 8, 2021. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-amivantamab-vmjw-metastatic-non-small-cell-lung-cancer

• PubMed
U.S. Food & Drug Administration. FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer. Accessed July 8, 2021. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-amivantamab-vmjw-metastatic-non-small-cell-lung-cancer)| false
• Search Google Scholar
• Export Citation

Yun J, Lee SH, Kim SY, et al. Antitumor activity of amivantamab (JNJ-61186372), an EGFR-Met bispecific antibody, in diverse models of EGFR exon 20 insertion-driven NSCLC. Cancer Discov 2020;10: 1194–1209.

• PubMed
Yun J, Lee SH, Kim SY, Antitumor activity of amivantamab (JNJ-61186372), an EGFR-Met bispecific antibody, in diverse models of EGFR exon 20 insertion-driven NSCLC. Cancer Discov 2020;10: 1194–1209.32414908)| false
• Search Google Scholar
• Export Citation

Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc enhanced EGFR/cMET bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis. Mol Cancer Ther 2020;19:2044–2056.

• Crossref
• PubMed
Vijayaraghavan S, Lipfert L, Chevalier K, Amivantamab (JNJ-61186372), an Fc enhanced EGFR/cMET bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis. Mol Cancer Ther 2020;19:2044–2056.10.1158/1535-7163.MCT-20-0071)| false
• Search Google Scholar
• Export Citation

Haura EB, Cho BC, Lee JS, et al. JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2019;37(Suppl): Abstract 9009.

• Crossref
• PubMed
Haura EB, Cho BC, Lee JS, JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2019;37(Suppl): Abstract 9009.10.1200/JCO.2019.37.15_suppl.9009)| false
• Search Google Scholar
• Export Citation

Park K, John T, Kim SW, et al. Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2020;38(Suppl):Abstract 9512.

• Crossref
• PubMed
Park K, John T, Kim SW, Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2020;38(Suppl):Abstract 9512.10.1200/JCO.2020.38.15_suppl.9512)| false
• Search Google Scholar
• Export Citation

Sabari JK, Shu CA, Park K, et al. Amivantamab in post-platinum EGFR exon 20 insertion mutant non-small cell lung cancer. J Thorac Oncol 2021;16:S108–109.

• Crossref
• PubMed
Sabari JK, Shu CA, Park K, Amivantamab in post-platinum EGFR exon 20 insertion mutant non-small cell lung cancer. J Thorac Oncol 2021;16:S108–109.10.1016/j.jtho.2021.01.284)| false
• Search Google Scholar
• Export Citation

Doebele X, Riely GJ, Spira K, et al. First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non-small cell lung cancer [abstract]. J Clin Oncol 2018;36(Suppl):Abstract 9015.

• Crossref
• PubMed
Doebele X, Riely GJ, Spira K, First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non-small cell lung cancer [abstract]. J Clin Oncol 2018;36(Suppl):Abstract 9015.10.1200/JCO.2018.36.15_suppl.9015)| false
• Search Google Scholar
• Export Citation

Neal J, Doebele R, Riely G, et al. Safety, PK, and preliminary antitumor activity of the oral EGFR/HEER2 exon 20 inhibitor TAK-788 in NSCLC. J Thorac Oncol 2018;13:S599.

• Crossref
• PubMed
Neal J, Doebele R, Riely G, Safety, PK, and preliminary antitumor activity of the oral EGFR/HEER2 exon 20 inhibitor TAK-788 in NSCLC. J Thorac Oncol 2018;13:S599.10.1016/j.jtho.2018.08.901)| false
• Search Google Scholar
• Export Citation

Janne PA, Neal JW, Camidge DR, et al. Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions [abstract]. J Clin Oncol 2019;37(Suppl):Abstract 9007.

• Crossref
• PubMed
Janne PA, Neal JW, Camidge DR, Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions [abstract]. J Clin Oncol 2019;37(Suppl):Abstract 9007.10.1200/JCO.2019.37.15_suppl.9007)| false
• Search Google Scholar
• Export Citation

Zhou C, Ramalingam S, Li B, et al. Mobocertinib in NSCLC with EGFR exon 20 insertions: results from the EXCLAIM and pooled platinum- pretreated patient populations. J Thorac Oncol 2021;16:S108.

• Crossref
• PubMed
Zhou C, Ramalingam S, Li B, Mobocertinib in NSCLC with EGFR exon 20 insertions: results from the EXCLAIM and pooled platinum- pretreated patient populations. J Thorac Oncol 2021;16:S108.10.1016/j.jtho.2021.01.283)| false
• Search Google Scholar
• Export Citation

Robichaux JP, Elamin YY, Vijayan RSK, et al. Pan-cancer landscape and functional analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity. Cancer Cell 2019;36:444–457.e7.

• Crossref
• PubMed
Robichaux JP, Elamin YY, Vijayan RSK, Pan-cancer landscape and functional analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity. Cancer Cell 2019;36:444–457.e7.10.1016/j.ccell.2019.09.001)| false
• Search Google Scholar
• Export Citation

Heymach J, Negrao M, Robichaux J, et al. A phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC) [abstract]. J Thorac Oncol 2018;13(Suppl):S323–324. Abstract OA02.06.

• Crossref
• PubMed
Heymach J, Negrao M, Robichaux J, A phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC) [abstract]. J Thorac Oncol 2018;13(Suppl):S323–324. Abstract OA02.06.10.1016/j.jtho.2018.08.243)| false
• Search Google Scholar
• Export Citation

Le X, Goldman JW, Clarke JM, et al. Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients [abstract]. J Clin Oncol 2020;38(Suppl): Abstract 9514.

• Crossref
• PubMed
Le X, Goldman JW, Clarke JM, Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients [abstract]. J Clin Oncol 2020;38(Suppl): Abstract 9514.10.1200/JCO.2020.38.15_suppl.9514)| false
• Search Google Scholar
• Export Citation

Cornelissen R, Garassino MC, Le X, et al. Updated efficacy, safety and dosing management of poziotinib in previously treated EGFR and HER2 exon 20 NSCLC patients. Presented at the 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28–31, 2021; Singapore.

• PubMed
Cornelissen R, Garassino MC, Le X, Updated efficacy, safety and dosing management of poziotinib in previously treated EGFR and HER2 exon 20 NSCLC patients. Presented at the 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28–31, 2021; Singapore.)| false
• Search Google Scholar
• Export Citation

Harvey RD, Adams VR, Beardslee T, et al. Afatinib for the treatment of EGFR mutation-positive NSCLC: a review of clinical findings. J Oncol Pharm Pract 2020;26:1461–1474.

• Crossref
• PubMed
Harvey RD, Adams VR, Beardslee T, Afatinib for the treatment of EGFR mutation-positive NSCLC: a review of clinical findings. J Oncol Pharm Pract 2020;26:1461–1474.3256749410.1177/1078155220931926)| false
• Search Google Scholar
• Export Citation

Roselló S, Blasco I, García Fabregat L, et al. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. Ann Oncol 2017;28(Suppl 4):iv100–118.

• Crossref
• PubMed
Roselló S, Blasco I, García Fabregat L, Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. Ann Oncol 2017;28(Suppl 4):iv100–118.2888191410.1093/annonc/mdx216)| false
• Search Google Scholar
• Export Citation

Passaro A, Mok T, Peters S, et al. Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations. J Thorac Oncol 2021;16:764–773.

• Crossref
• PubMed
Passaro A, Mok T, Peters S, Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations. J Thorac Oncol 2021;16:764–773.3333332710.1016/j.jtho.2020.12.002)| false
• Search Google Scholar
• Export Citation

Kobayashi Y, Togashi Y, Yatabe Y, et al. EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first- or third-generation TKIs. Clin Cancer Res 2015;21:5305–5313.

• Crossref
• PubMed
Kobayashi Y, Togashi Y, Yatabe Y, EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first- or third-generation TKIs. Clin Cancer Res 2015;21:5305–5313.10.1158/1078-0432.CCR-15-1046)| false
• Search Google Scholar
• Export Citation

Cummings AL, Boni V, Dooms C, et al. Neratinib efficacy in patients with EGFR exon18-mutant non-small lung cancer (NSCLC): findings from the SUMMIT Basket trial. Presented at the IASLC 2021 Targeted Therapies of Lung Cancer Meeting, Worldwide Virtual Event; February 20, 2021. Abstract S12.02.

• PubMed
Cummings AL, Boni V, Dooms C, Neratinib efficacy in patients with EGFR exon18-mutant non-small lung cancer (NSCLC): findings from the SUMMIT Basket trial. Presented at the IASLC 2021 Targeted Therapies of Lung Cancer Meeting, Worldwide Virtual Event; February 20, 2021. Abstract S12.02.)| false
• Search Google Scholar
• Export Citation

Li BT, Shen R, Buonocore D, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol 2018;36:2532–2537.

• Crossref
• PubMed
Li BT, Shen R, Buonocore D, Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol 2018;36:2532–2537.10.1200/JCO.2018.77.977729989854)| false
• Search Google Scholar
• Export Citation

Tsurutani J, Park H, Doi T, et al. Updated result of phase 1 study of DS-8201A in HER2-expressing or -mutated advanced non-small-cell lung cancer. Presented at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer; September 24, 2018; Toronto, Canada.

• PubMed
Tsurutani J, Park H, Doi T, Updated result of phase 1 study of DS-8201A in HER2-expressing or -mutated advanced non-small-cell lung cancer. Presented at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer; September 24, 2018; Toronto, Canada.)| false
• Search Google Scholar
• Export Citation

Smit EF, Nakagawa K, Nagasaka M, et al. Trastuzumab deruxtecan (T-DXd; D-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): interim results of DESTINY-Lung01 [abstract]. J Clin Oncol 2020;38(Suppl):Abstract 9504.

• Crossref
• PubMed
Smit EF, Nakagawa K, Nagasaka M, Trastuzumab deruxtecan (T-DXd; D-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): interim results of DESTINY-Lung01 [abstract]. J Clin Oncol 2020;38(Suppl):Abstract 9504.10.1200/JCO.2020.38.15_suppl.9504)| false
• Search Google Scholar
• Export Citation

Socinski MA, Cornelissen R, Garassino MC, et al. ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations. Ann Oncol 2020;31(Suppl 4):S1142–1215.

• Crossref
• PubMed
Socinski MA, Cornelissen R, Garassino MC, ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations. Ann Oncol 2020;31(Suppl 4):S1142–1215.10.1016/j.annonc.2020.08.2293)| false
• Search Google Scholar
• Export Citation